Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

Zhaoshen Li

Status

Enrolling

Conditions

DNA Methylation

Proteome

Pancreatic Neoplasms

Treatments

Diagnostic Test: cfDNA methylation sequencing and proteome analysis

Study type

Observational

Funder types

Other

Identifiers

NCT05737953

WKX2023-02

Details and patient eligibility

About

The goal of this observational study is to test in patients with cystic tumor of pancreas. The main questions it aims to answer are:

Screening of molecular diagnostic markers for pancreatic cystic tumors by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic assays to distinguish benign from malignant and mucinous/non-mucinous, correlate with pathological features, and find molecular features associated with the degree of malignancy.

Participants will Provide post-operative cyst fluid specimens.

Full description

Patients with pancreatic cystic tumors were divided into control, mucinous tumor and non-mucinous tumor groups, and cfDNA molecules and protein molecules that were significantly altered between different groups were found by cfDNA methylation sequencing of pancreatic cystic fluid and proteomic detection techniques. Multi-omics analysis was performed to construct a more efficient molecular diagnostic marker model. Correlating models with pathological features to find molecular features associated with the degree of malignancy.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects are ≥ 18 years old, regardless of gender;
Preoperative imaging examination (EUS, CT, MRI) diagnosed cystic mass of pancreas and suspected cystic tumor;
Subjects voluntarily accepted radical resection of pancreatic cystic tumors;
Subjects or family members voluntarily sign the informed consent form for clinical research.

Exclusion criteria

The excised sample does not contain cystic components, or the cystic fluid cannot be collected;
Receive tumor-related treatment (radiotherapy, chemotherapy, immunotherapy, etc.) before operation;
Receive antibiotic treatment within 1 week before operation;
Subjects refused to accept radical resection of pancreatic cystic tumor, or had any situation that they could not accept radical resection of pancreatic cystic tumor;
The subjects or their families refused to sign the informed consent form for clinical research.